Literature DB >> 4024217

A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin.

R A Brandon, M J Eadie, M T Smith.   

Abstract

An original, highly sensitive and specific high performance liquid chromatographic method has been developed for the measurement of aspirin and salicylate in plasma. Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma. After collection, plasma is first treated with physostigmine sulfate to inhibit enzymatic hydrolysis of aspirin to salicylate. Maximal recovery is achieved using an acid extraction into anhydrous diethyl ether with a subsequent drying-down step in an iced water bath. Aspirin and salicylate are separated by elution with a mixture of methanol, 1-butanol, orthophosphoric acid, and water on a reversed-phase octadecyl silane column at 47 degrees C and detected at 234 nm by ultraviolet absorption. Quantitation is achieved using the peak height ratio of aspirin and salicylate to internal standard (m-anisic acid). The assay has been used for the study of simultaneous aspirin and salicylate pharmacokinetics after a single oral dose of 100 mg soluble glycinated aspirin for platelet antiaggregatory therapy in six subjects, one of whom was also studied after receiving a 600 mg dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024217     DOI: 10.1097/00007691-198506000-00014

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  2 in total

1.  Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.

Authors:  F Bochner; D B Williams; P M Morris; D M Siebert; J V Lloyd
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding.

Authors:  P J Prichard; T J Poniatowska; J E Willars; A T Ravenscroft; C J Hawkey
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.